Valeant selling US$2.1b in assets to pay down debt
Paris
VALEANT Pharmaceuticals International Inc, the embattled Canadian drugmaker, has agreed to sell about US$2.1 billion in assets to get cash to streamline its businesses and begin easing its debt burden.
L'Oreal SA will pay Valeant US$1.3 billion for three skincare brands, the Paris-based company said in a statement on Tuesday. Earlier in the day, Valeant said that it would sell its Dendreon Pharmaceuticals unit to closely held Chinese conglomerate Sanpower Group Co for about US$820 million.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
DBS customers unable to log into Digibank, PayLah! on Thursday
Japan’s Sumitomo Corp net profit down 32% on Madagascar one-off loss
Moody's tops quarterly profit estimates on strong product demand
Hong Kong regulator brings insider trading charges against Segantii and its founder
Novartis to buy radiology specialist Mariana Oncology for US$1 billion
Moderna beats quarterly estimates as cost-cutting pares losses